RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals
On December 08, 2022 the international biotech consulting company PwC wrote: "As the overall economic outlook stabilizes somewhat, the need to invest to achieve transformation will remain unparalleled. Achieving scale to deliver shareholder value is imperative. We continue to expect that deals in the $5 billion to $15 billion range will be the market sweet spot but see the potential for larger deals in the second half of the year.
We expect to see activity in areas of high expected future growth in 2023. Pharma and biotech M&A will continue to focus on oncology and immunology"
https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html
The overall focus now is the number of different patents that are going to roll off-patent with this triggering a heavy CapEx or acquisition spending environment for some of these biotech or biopharma companies as they are about to have a difficult period of the patent exclusivities, at a time when it is very difficult to generate new drugs. [ Advantage Oncolytics Biotech : ONCY / ONC.TO ]
Such independent opinions of managing directors/biotech analysts continue to confirm what has been posted on this message board over the approximately past 6 months in that Big Pharma companies is looking for "bolt-on" M&A deals that fall within their "sweet spot" of between US$5 Billion to US$ 15 Billion.